**Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells**

Li Wang,1,2* Wen-Yu Shi,1* Fan Yang,1,2* Wei Tang,1* Guillaume Gapihan,2,3,4,5 Mariana Varna,2,3,4,5 Zhi-Xiang Shen,1 Sai-Juan Chen,1,2 Christophe Leboeuf,2,3,4,5 Anne Janin,2,3,4,5 and Wei-Li Zhao1,2

1State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China; 3Inserm, U728, Paris, France; 4Université Paris 7, Paris, France; and 5AP-HP, Hôpital Saint-Louis, Service de Pathologie, Paris, France


**SUPPLEMENTARY APPENDIX**

**Online Supplementary Figure S1.** Bevacizumab interrupted tumor-endothelial cell interaction through ICAM-1 downregulation. (A) In vivo, an immunohistochemical study using anti-human and anti-mouse ICAM-1 antibodies showed that doxorubicin induced ICAM-1 expression on tumor cells and on mouse endothelial cells. Addition of bevacizumab decreased doxorubicin-induced ICAM-1 expression, bar=20 μm, *P<0.05. (B) In vitro, soluble ICAM-1 (left panel) and membrane ICAM-1 (right panel) were detected in cell culture by ELISA and flow cytometry, respectively. Left panel: when co-cultured in the same vial, combined bevacizumab and doxorubicin significantly inhibited doxorubicin-induced ICAM-1 expression. This was not observed in the co-culture system with 1 μM pore millicell filter, which prevented direct contact between tumor and endothelial cells. Co-culture in the same vial, Co-culture with 1 μM pore millicell filter, *P<0.05. Right panel: when co-cultured in the same vial, the doxorubicin-induced ICAM-1 was also inhibited by bevacizumab treatment. (C) Lymphoma-endothelial cell adhesion tests showed that cell adhesion was significantly decreased with bevacizumab and doxorubicin, when compared with doxorubicin alone. *P<0.05 bar=20 μm. (D) On confocal microscope, doxorubicin induced close association of endothelial (arrows) and tumor cells (arrowheads), and strong ICAM-1/LFA-1 expression on endothelial cells, especially in areas where endothelial and tumor cells were in close contact. Addition of bevacizumab abrogated ICAM-1 expression by endothelial cells, and their close association with tumor cells.